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 Malaria is a life-threatening disease cause 216 million cases worldwide and almost 
445,000 deaths every year. Plasmodium sporozoite parasites injected by a 
female Anopheles mosquito, travel to the liver and infect hepatocytes, afterward the clinical 
phase of malaria infection occurred in blood stage. The liver-stage parasites 
asymptomatically produce thousands of merozoites that will subsequently infect erythrocytes. 
Therefore, an effective innate immune response raised before or during the liver-stage 
infection could prevent the onset of disease. Autographa californica nucleopolyhedrosis virus 
(AcNPV), a type of Baculovirus (BV), is an enveloped insect virus with a circular double-
stranded DNA genome, possesses unique characteristics to induce strong innate immune 
responses in various mammalian cells and in mice. The aim of my study was to assess the 
capability of the BV-induced innate immune responses for protecting mice against malaria 
pre-erythrocytic stage along with its adjuvant properties. 
 Here I show that the innate immune responses induced by BV not only eliminate 
Plasmodium liver-stage parasites but also elicit sterile protection against Plasmodium 
sporozoite infection through type I interferon (IFN) signaling pathway. Mice had infected 
with liver-stage parasites before 24 h completely prevented blood-stage parasites following 
single dose of BV intramuscular administration, which was much superior to primaquine 
(PQ), the only drug approved to eradicate liver-stage parasites indicating an excellent 
therapeutic effect as well as the short-term prophylactic effect. This BV-mediated liver-stage 
parasite elimination was also observed in TLR9-/- mice. In addition to the therapeutic effect, 
BV intramuscular administration sterilely protects mice for at least seven days from 
subsequence sporozoite infection, indicating the prophylactic effect. At 6 h post-BV 
administration, IFN-α and IFN-γ were robustly produced in the sera, and RNA transcripts of 
interferon-stimulated genes were drastically upregulated in the liver compared with control 
mice. The in vivo passive transfer with sera from mice intramuscularly administered with BV 
effectively eliminated liver-stage parasites and this effect was canceled by neutralization of 
IFN-α but not IFN-γ in the sera, indicating a killing mechanism downstream of type I IFN 
signaling pathway. In conclusion, my results provide a great potential of BV for development 
of BV-based vaccine and anti-hypnozoite drug as a new stand-alone therapeutic and 
prophylactic immunostimulatory agent with a killing mechanism downstream of type I IFN 
signaling pathway, which is applicable not only for malaria but also for other serious 
infectious diseases such as viral hepatitis and liver cancers. 
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Ab  antibody 
AcNPV Autographa californica nucleopolyhedrosis virus 
AdHu5 human adenovirus type 5 
AdHu5-luc recombinant AdHu5 expressing luciferase 
Ag  antigen 
ALT  alanine aminotransferase / alanine transaminase 
ANOVA analysis of variance 
AST  aspartate aminotransferase / aspartate transaminase 
BDES  baculovirus dual-expression system 
BES  baculovirus expression system 
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  under the control of the P. berghei CSP promoter 
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p.i.  post-infection 
PKR  protein kinase R  
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PRRs  pattern recognition receptors 
PQ  primaquine  
qRT-PCR real-time quantitative reverse transcription polymerase chain reaction 
RNaseL ribonuclease L 
RLU  relative luminescence units 
SEM  standard error mean 
Spz  sporozoites 
TLR  toll-like receptor 
TNF  tumor necrosis factor 
VLP  virus like particle 
VSV-G vesicular stomatitis virus G glycoprotein 
WHO  World Health Organization 





Malaria remains a severe public health problem and causes significant economic losses 
worldwide. In 2016, there were approximately 216 million malaria cases and an estimated 
445,000 malaria deaths, mainly in children under five years age (1). Malaria infection is initiated 
following injection of Plasmodium sporozoites injected into the skin during the taking of a blood 
meal by Anopheles mosquitoes. The sporozoites then migrate to the liver and invade hepatocytes. 
Before clinical symptoms of malaria occur during the blood stage of infection, Plasmodium 
falciparum in the liver develops into exoerythrocytic schizonts for 5 to 6 days. Plasmodium vivax 
and Plasmodium ovale can develop dormant liver-stage forms, known as hypnozoites, which 
cause relapsing blood-stage infections months or years after the primary infection. The clinically 
silent pre-erythrocytic stages of mammalian Plasmodium spp, composed of both the sporozoite 
and liver stages represent the first opportunity the mammalian host has to mount a defense 
against Plasmodium infection (2). Moreover, the liver-stage development compensates for the 
low numbers of transmitted sporozoites, a major bottleneck of the Plasmodium life cycle. 
Therefore, the pre-erythrocytic stages are deal targets for both the vaccine interventions and 
prophylactic drug discovery (2).  
Currently, the only licensed drug for the radical cure of P. vivax hypnozoites is 
artemisinin-based combination therapies and primaquine (PQ) which are recommended by the 
World Health Organization (WHO) as the first-line treatment for blood-stage P. falciparum 
malaria. Artemisinin-based combination therapies (ACTs) are recommended by WHO as the 
first-line treatment for uncomplicated Plasmodium falciparum malaria. However, artemisinin 
resistance has emerged in Southeast Asia, (3) and possible ACT-resistant P. falciparum malaria 
cases have been reported in Sub-Saharan Africa (4). Therefore, the WHO advocates increased 
monitoring and surveillance to identify and contain artemisinin resistance (5). For drug 
development against the liver-stage parasite, currently, the only licensed drug for the radical cure 
of P. vivax malaria is primaquine (PQ), which kills liver stage parasites, including hypnozoites 
(6). But, PQ has a high associated risk of life-threatening hemolytic anemia in people with 
glucose-6-phosphate-dehydrogenase enzyme (G6PD) deficiency (8). For future malaria 
eradication strategies, safer radical curative compounds that efficiently kill hypnozoites are 
required. The absence of a fully efficacious vaccine and continuous emergence of drug-resistant 
parasites pose a serious threat of malaria resurgence. Hence, to control the spread of malaria, 
development of a safe and fully efficacious control strategies is an urgent priority (5, 7).  
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A series of studies performed by Nussenzweig and colleagues in 1986-1987 revealed 
that exogenously administered IFN-γ effectively inhibits the development of liver-stage parasites 
in vitro and in vivo (8-11). Recently, Boonhok et al. reported that IFN-γ-mediated inhibition 
occurs at least partially in an autophagy-related protein-dependent manner in infected hepatocytes 
(12). Additionally, Liehl et al. reported that hepatocytes infected with wild type (WT) liver-stage 
parasites induce type I IFN secretion via host cell sensing of Plasmodium RNA, resulting in a 
reduction of the liver-stage burden (13). These findings suggest that IFN-mediated 
immunotherapy against liver-stage parasites might be effective. However, new anti-hypnozoite 
drugs (e.g. rIFNs or appropriate IFN inducers) have not been developed yet.  
Autographa californica nucleopolyhedrosis virus (AcNPV), a type of baculovirus (BV), 
is an enveloped, double-stranded DNA virus that naturally infects insects. BVs possess unique 
characteristics that activate dendritic cell (DC)-mediated innate immunity through both 
MyD88/Toll-like receptor 9 (TLR9)-dependent and -independent pathways (14). Takaku and 
colleagues reported that BV also directly activates murine natural killer (NK)-cells through the 
TLR9 signalling pathway (15, 16), which leads to the induction of NK cell-dependent anti-
tumour immunity. With the outstanding adjuvant properties on maturation of DC and activation 
of NK cells, BV has recently emerged as a new vaccine vector with several other attractive 
attributes, including (i) low cytotoxicity, (ii) an inability to replicate in mammalian cells, and (iii) 
an absence of preexisting antibodies. Our lab has developed BV-based malaria vaccines effective 
for all three parasite stages, the pre-erythrocytic stage (17-19), asexual blood stage (20, 21), and 
sexual stage (22, 23).  
Here, I investigated BV-mediated innate immunity against the pre-erythrocytic stage 
parasites. My results clearly demonstrate that BV intramuscular administration not only elicits 
short-term sterile protection against Plasmodium sporozoite infection but also eliminates liver-
stage parasites completely through the type I IFN signalling pathway. I propose that, due to its 
potent IFN-inducing characteristics, BV has the potential to be developed not only as a new 
malaria vaccine additive capable of protecting vaccine recipients for a short period before and 
after malaria infection but also as a new non-haemolytic single-dose drug.  
	 3 
AIMS OF THE STUDY 
 
 BV is an enveloped insect virus with a circular double-stranded DNA genome, 
possesses unique characteristics to induce strong innate immune responses in various 
mammalian cells and in mice. Stimulation of innate immune system is a prerequisite for 
generating robust and long-lasting adaptive immune responses. Immune potentiators (e.g., 
TLR agonists or cytokines) function by activating innate immune responses, leading to 
enhanced antigen presentation. Therefore, an effective innate immune response raised before 
or during the liver-stage infection could prevent the onset of disease.  
 The overall aim of this thesis was to examine the characteristics features of BV with 
activation of innate immunity. In the long run, I was chasing against the malaria pre-
erythrocytic stage by exploiting the adjuvant properties of baculoviral vector. 
 
In addition, the specific aims of the study were: 
- To investigate whether BV-mediated innate immunity could protect animals against 
malaria challenge infection. 
- To study whether BV-mediated innate immunity could eliminate the existing liver-
stage parasites. 
- To assess whether BV possessed more prophylactic effectiveness than CpG. 
- To evaluate whether BV possessed better therapeutic effectiveness than PQ. 
- To identify the role of TLR9 in BV-mediated liver-stage parasite elimination. 
- To check the interferon’s (IFNs) dependent killing mechanism. 




MATERIALS AND METHODS 
 
Animals and cell lines 
 Female inbred BALB/c (H-2d) mice were obtained from Japan SLC (Hamamatsu, 
Shizuoka, Japan) and used in all experiments at 7-8 weeks of age. TLR9-deficient (TLR9-/-) 
mice on a BALB/c background were kindly provided by Shizuo Akira (University of Osaka, 
Suita, Japan). Spodoptera frugiperda (Sf9) and HepG2 cells were maintained as according to 
the standard protocol (18). Mice were anesthetized with ketamine (100 mg/kg; intramuscular; 
Daiichi Sankyo, Tokyo, Japan) and xylazine (10 mg/kg; intramuscular; Bayer, Tokyo, Japan) 
when necessary. 
 
Parasites and mosquitoes 
 The Anopheles stephensi mosquito strain SDA 500 was maintained at the Kanazawa 
University according to a standard protocol (17, 24). Three transgenic P. berghei ANKA 
parasites were used in this my study: green fluorescent protein (GFP)-P. berghei (Pb-
conGFP) (25), luciferase-P. berghei (Pb-Luc) (26), and P. falciparum cirucumsporozoite 
(PfCSP)-P. berghei (PfCSP-Tc/Pb) (27). Transgenic PfCSP-Tcell (Tc)/Pb parasites were 
generated to replace the PbCSP gene with PfCSPA361E using the same method as described 
previously (27, 28). These transgenic parasites were maintained by cyclical passaging 
through BALB/c mice and A. stephensi (SDA 500 strain) at the Kanazawa University and 
Jichi Medical University according to a standard protocol (17, 24).  
 
Parasite production and sporozoite collection 
 Transgenic parasites used to challenge mice were produced at the insectary of 
Laboratory of Vaccinology & Applied Immunology, Kanazawa University. A. stephensi 
mosquitoes (SDA 500 strain) were infected either with Pb-conGFP, Pb-Luc, or PfCSP-Tc/Pb 
by allowing them to feed on parasite-infected mice. The condition of the parasites (in terms 
of their infectivity) to recipient mice was checked by exflagellation tests before blood feeding 
commenced. Mosquitoes were exposed to anaesthetized infected mice for 10-30 minutes. 
Mosquitoes were then maintained for 21 days in a humidified incubator at a temperature of 
19–21 °C on a 12-hour day-night cycle and fed with a fructose/PABA solution. On day 18 to 
21 after infection, the salivary glands of the mosquitoes were collected by hand-dissection. 
The mosquitoes used for challenge had salivary gland sporozoite infection rates of 60 to 90% 
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at 18 to 21 days after the infectious blood meal. Salivary glands were collected in DMEM 
(Thermo Fisher Scientific K.K., Tokyo, Japan) or RPMI-1640 media (Gibco, Life 
technologies) and homogenized by a plastic homogenizer. The free sporozoites were counted 




 The recombinant BVs BES-GL3 and BDES-sPfCSP2-WPRE-Spider have been 
described previously (29). Recombinant baculovirus, BES-GL3-Spider was designed to 
express the luciferase gene under the control of the pCMV single promoter, which also 
contains a gene cassette for hDAF display as described previously (17, 20). Purification of 
viral particles was performed as described previously (17). The purified BV particles were 
free of endotoxin (<0.01 endotoxin units/109 PFU), as determined by the Endospecy® 
endotoxin measurement kit (Seikagaku Co., Tokyo, Japan). The recombinant adenovirus, 
AdHu5-Luc was designed to express the luciferase gene under the control of the CAG 
promoter, as described earlier (18). To generate the human type 5 adenoviral vector AdHu5-
sPfCSP2, the gene cassette encoding the GPI-anchor lacking PfCSP (Leu19-Val367) fused to 
VSV-G protein membrane anchor sequence with followed by a wpre sequence was excised 
from pFast-sPfCSP2-WPRE-Spider (30) by digestion with EcoRI and XhoI and then inserted 
into the EcoRI and XhoI sites of pAd/PL-DEST (Invitrogen, Carlsbad, CA, USA) under the 
control of CAG promoter sequences. Purification and titration of adenovirus were carried out 
using fast-trap adenovirus purification and concentration kits (Millipore, Temecula, CA, 
USA) and Adeno-X™ Rapid Titer Kit (Clontech, Palo Alto, CA), respectively, according to 
the manufacturer's protocols. In this thesis, BDES-sPfCSP2-WPRE-Spider and AdHu5-
sPfCSP2 are described as BDES-PfCSP and AdHu5-PfCSP, respectively.  
 
Analysis of protective effects against sporozoite parasites 
 BALB/c mice were intravenously, intramuscularly, or intranasally administered 104–
108 plaque forming units (pfu) of BES-GL3. Alternatively, instead of BES-GL3, BALB/c 
mice were intramuscularly injected with 50 µg of CpG ODN 1826 
(TCCATgACgTTCCTgACgTT, Fasmac Inc., Tokyo, Japan). The mice were intravenously 
challenged with 1,000 Pb-conGFP sporozoites or 1,000 blood-stage parasite-infected red 
blood cells at various time intervals (6 h–14 days). The mice were checked for P. berghei 
blood-stage infection by microscopic examination of Giemsa-stained thin smears of their tail 
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blood, prepared on days 5, 6, 7, 8, 11, and 14 post-challenge. The time required to reach 1% 
parasitaemia was determined as described previously (31). A minimum of 20 fields 
(magnification: 1,000×) were examined before a mouse was deemed to be negative for 
infection. The percentage of parasitaemia was calculated as follows: parasitaemia (%) = 
[(number of infected erythrocytes)/(total number of erythrocytes counted)] × 100. Protection 
was defined as the complete absence of blood-stage parasitaemia on day 14 post-challenge. 
 
Analysis of elimination effects on liver-stage parasites 
 BALB/c mice were intravenously injected with 1,000 Pb-conGFP sporozoites and 
then intravenously (107 pfu) or intramuscularly (108 pfu) injected with BES-GL3 at various 
time intervals (6, 24, or 42 h post-infection). Alternatively, instead of BV, a single high (2 
mg) or low (0.1 mg) dose of PQ (primaquine diphosphate 98%, Sigma-Aldrich, St. Louis, 
MO, USA), with corresponding concentrations of roughly 100 mg/kg body weight and 5 
mg/kg body weight respectively, was intraperitoneally administered 24 h after the injection of 
1,000 Pb-conGFP sporozoites. The mice were checked for P. berghei blood-stage infection 
and evaluated for 1% parasitaemia as described above. 
 
In vivo bioluminescent imaging 
 Luciferase activity in mice was visualized through imaging of whole bodies using in 
vivo imaging system, IVIS (PerkinElmer, Waltham, MA, USA) as described previously (32-
34). BALB/c mice were intravenously or intramuscularly injected with BES-GL3 on day 0, 
and D-luciferin (15 mg/ml; OZ Biosciences, Marseille, France) was then intraperitoneally 
administered (150 µl/mouse) to these mice at various timepoints. The animals were 
anesthetized with a ketamine (100 mg/kg)/xylazine (10 mg/kg) mixture 10 min later, and the 
luciferase expression was detected with an in vivo imaging system, IVIS® Lumina LT in vivo 
imaging system (PerkinElmer, Waltham, MA, USA). Alternatively, BALB/c mice were 
intravenously injected with 1,000 Pb-Luc sporozoites followed 24 or 42 h later by 
intramuscular administration of BES-GL3 (108 pfu) into the left thigh muscle. At 72 h after 
the sporozoite injection, the luciferase expression was detected as described above. At days 
5-14 post-infection, the same mice were analysed for blood-stage infections by determination 






 BALB/c mice were intravenously or intramuscularly injected with BV, and serum 
samples were subsequently harvested from whole blood obtained by cardiopuncture at 
various times and stored at −20 °C until analysis. The concentrations of cytokines in the sera 
were determined by sandwich ELISA using a Mouse IFN-γ ELISA MAX™ standard kit 
(Biolegend Inc., San Diego, CA, USA), mouse IL-12/IL-23 (p40) ELISA MAX™ standard 
kit (Biolegend Inc.), or mouse TNF-α ELISA MAX™ deluxe kit (Biolegend Inc.) according 
to the manufacturer’s instructions. Briefly, ninety-six-well plates (Corning Inc.; Corning, NY, 
USA) was coated with the capture Ab (100 µl, 1:200), diluted in coating buffer (8.4 g 
NaHCO3, 3.56 g Na2CO3 in 1L DI H2O, pH 9.5) for overnight at 4 °C. After washing four 
times with PBS containing 0.05% Tween 20 (200 µl, washing buffer) and blocking with PBS 
containing 1% BSA (200 µl, assay diluent) for 1 h at room temperature. After washing the 
plates four times in ELISA washing buffer, diluted samples (in assay diluent) of either sera or 
cytokine standards were dispensed in duplicate (100 µl/well) and the plates incubated for at 
37 °C for 2 h. Standards were serially diluted with assay diluent according to manufacturer’s 
protocol. The plates were then washed as before and added detector mouse biotinylated 
cytokine (IFN-γ, TNF-α, and IL-12) at dilutions of 1:200 (100 µl/well). This was followed by 
incubation at 37 °C for 1 h, and washed as before. Streptavidin horseradish peroxidase (SA-
HRP; Sigma, USA) diluted 1:1000 in assay diluent was added 100 µl/well and incubated at 
37 °C for 30 min before a further six washes. Color development was achieved by adding 
100 µl/well of tetramethylbenzidene (TMB) substrate solution A : B in equal proportion 
(1:1). After incubating for 30 min at room temperature, the optical density was measured at 
450 and 570 nm on a multiskan bichromatic microplate reader (Thermo Lab systems, Vantaa, 
Finland) following the addition of 100 µl of stop solution (1 N H2SO4). IFN-γ, TNF-α, and 
IL-12 concentration was calculated using a standard curve according to kit protocol. 
 The IFN-α concentration was determined by sandwich ELISA as described previously 
(13). In brief, rat monoclonal antibody against mouse IFN-α (clone RMMA-1; PBL 
Biomedical Laboratories Piscataway, NJ, USA) was used as the capture antibody (2 µg/ml 
for coating), rabbit polyclonal antibody against mouse IFN-α (PBL Biomedical Laboratories) 
was used at 80 neutralizing units per ml for detection, and HRP-conjugated goat anti-rabbit 
IgG (Bio-Rad Laboratories, Hercules, CA, USA) was used as the secondary reagent. 
Recombinant mouse IFN-α (PBL Biomedical Laboratories) was used as the standard. The 
lower detection limits for the IFN-γ and IFN-α immunoassays were each <20 pg/ml, whereas 
those for the IL-12 and TNF-α immunoassays were each <10 pg/ml.  
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Aspartate transaminase (AST) and alanine transaminase (ALT) assays 
 Serum samples from intravenously or intramuscularly injected mice with BV were 
collected at various times by cardiopuncture method and stored at −20 °C until analysis. The 
levels of alanine transaminase (ALT/GPT) and aspartate transaminase (AST/GOT) from the 
sera were determined by using a GPT/GOT assay kit (Transaminase CII-test; Wako Pure 
Chemical Industries, Ltd., Japan), according to manufacturer’s instruction. The 
manufacturer’s instructions were precisely followed. 
 
Serum transfer and IFN administration analysis 
 Pooled sera were obtained from blood harvested by cardiopuncture from five BALB/c 
mice that had been intramuscularly injected 6 h previously (at −6 h) with BES-GL3, and the 
concentrations of IFN-α and IFN-γ were measured immediately. On the same day, the IFN-α 
and IFN-γ in 100 µl aliquots of the pooled sera were neutralized by incubation on ice for 6 h 
with anti-IFN-α (anti-mouse interferon alpha, rabbit serum; PBL Biomedical Laboratories) 
and anti-IFN-γ (Ultra-LEAFTM purified anti-mouse IFN-γ antibody; Biolegend Inc.) 
antibodies, respectively, according to the manufacturer’s instructions. At 24 h after being 
intravenously injected with 1,000 Pb-conGFP sporozoites, BALB/c mice were subsequently 
intravenously injected with 100 µl of the sera that had been treated with either anti-IFN-α or 
anti-IFN-γ. For the IFN administration experiment, BALB/c mice that had been intravenously 
injected with 1,000 Pb-conGFP sporozoites 24 h before were then intravenously administered 
either 8,619 pg of IFN-α or 4,705 pg of IFN-γ. For each experiment, the mice were checked 
for P. berghei blood-stage infection and evaluated for 1% parasitaemia as described above. 
 
RNA isolation from livers and qRT-PCR quantification 
 BALB/c (WT or TLR9-/-) mice were intramuscularly injected with 108 pfu of BES-
GL3. Alternatively, 50 µg of CpG ODN 1826 were administered intramuscularly. Six hours 
later, whole livers were obtained by dissection of the treated mice. Each whole liver was 
placed in a 5-ml plastic tube with a cap containing 4 ml of buffer RLT (Qiagen, Valencia, 
CA, USA) containing 1% 2-mercaptoethanol. Two stainless steel beads (5-mm external 
diameter) were added to the mixture. Once the tube was capped, it was attached to a µT-12 
Beads Crusher (TAITEC, Saitama Japan), and vigorously shaken at 2,500 rpm for 3.5 min. 
Total RNA was isolated from 100-µl aliquots of the homogenates by using an RNeasy kit 
(Qiagen). cDNA was synthesized by using random hexamers and Multiscribe reverse 
transcriptase (Applied Biosystems, Foster City, CA, USA). Quantitative analysis of RNA 
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transcripts was performed by Real-time PCR with SYBR® Green Premix Ex Taq™ (Takara, 
Tokyo, Japan) and the following primer sets:  
gapdh (F: TGCCCCCATGTTTGTGATG, R: TGTGGTCATGAGCCCTTCC),  
mx1 (F: AACCCTGCTACCTTTCAA, R: AAGCATCGTTTTCTCTATTTC),  
oas1a (F: ACTCCTTTGTGGCTCAGTGG, R: ACCAGCTCCACGTCTGTAGTG),  
oas1b (F: TTCTACGCCAATCTCATCAGTG, R: GGTCCCCCAGCTTCTCCTTAC),  
oasl1 (F: ATGTTAATACTTCCAGCAAGC, R: GCAAAGACAGTGAGCAACTCT),  
pkr (F: GATGGAAAATCCCGAACAAGGAG, R: AGGCCCAAAGCAAAGATGTCCAC), 
ifit1 (F: CCTTTACAGCAACCATGGGAGA, R: GCAGCTTCCATGTGAAGTGAC),  
ifit3 (F: CTGAACTGCTCAGCCCACAC, R: TGGACATACTTCCTTCCCTGA),  
ifit44 (F: TCGATTCCATGAAACCAATCAC, R: CAAATGCAGAATGCCATGTTTT),  
irf3 (F: GATGGCTGACTTTGGCATCT, R: ACCGGAAATTCCTCTTCCAG),  
irf7 (F: CTTCAGCACTTTCTTCCGAGA, R: TGTAGTGTGGTGACCCTTGC).  
Amplification of gapdh was performed in each experiment. The Ct value of each sample was 
standardized based on the gapdh Ct value (∆Ct), and each ∆Ct value was normalized to that 
of the ∆Ct value from PBS-treated control WT mice (∆∆Ct). Results are shown as the relative 
expression (1/2∆∆Ct). 
 
Protective efficacy of heterologous human adenovirus serotype 5 (AdHu5)-prime/BV 
dual expression system (BDES)-boost immunization against sporozoite challenge 
 Recombinant viruses expressing PfCSP, AdHu5-PfCSP, or BDES-PfCSP have been 
described previously (19, 29). BALB/c mice were first intramuscularly immunized with 
AdHu5-PfCSP (5 × 107 pfu). After 3 weeks, the mice were intravenously challenged with 
1,000 PfCSP-Tc/Pb sporozoites, and, after 24 h, the mice were then intramuscularly 
immunized either with BDES-PfCSP (1 × 108 pfu) or PBS. The mice were checked for P. 
berghei blood-stage infection and evaluated for 1% parasitaemia as described above. 
Protected mice were intravenously re-challenged with 1,000 PfCSP-Tc/Pb sporozoites, and 
protection was defined as described above. 
 
Statistical analysis 
 Details concerning the study outline, sample size, and statistical analysis are shown in 
the main text, figures, and figure legends. A two-tailed Fisher’s exact probability test was 
performed to determine the significance of differences in the protective efficacies of the 
vaccines, using SPSS software (version 19, Chicago, IL, USA). In all other experiments, 
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statistical differences between the experimental groups were analysed by the methods 
described in the individual figure legends; p values of <0.05 were considered statistically 
significant. Statistical analyses were performed with either Prism version 7.0a (GraphPad 




Construction of recombinant BV 
Construction of BES-GL3 Spider (BV) is shown in Figure 1. I used the BV called 
BES-GL3, which harbours two gene cassettes consisting of the luciferase gene under the 
control of the CMV immediate-early enhancer-promoter (pCMViep) promoter and the decay 
accelerating factor (DAF) gene under the control of the p10 promoter. The gene encoding 
EGFP was driven invertedly by the polyhedrin promoter (pPolh). BES-GL3 was designed to 
express luciferase as a transducing marker and to display DAF as protection for BV from 
complement attack, respectively (29). 
 
BV administration induces transgene expression and innate immune responses   
 BV is a promising gene therapy vector capable of transducing broad range of 
mammalian cells in vitro with significant efficiency leading to stable gene expression (35, 
36). BES-GL3 intramuscular administration into the left thigh muscle of mice initially 
increased the luciferase expression levels robustly, but these levels gradually decreased to 2% 
on day 28 (Figure 2A), which is consistent with findings from previous studies (29, 37). 
Among the various cell types tested in vitro, hepatocytes were found to be the most effective 
at taking up BV (38), suggesting a potential use for BV as a vector for liver-directed gene 




Figure 1: Schematic representation of the luciferase-expressing BV. BES-GL3 
Spider vectors express firefly luciferase GL3 under the pCMV promoter and contain a 




reported previously because BV-mediated gene transfer into hepatocytes via intravenous 
injection is severely hampered by serum complement (39). Here, use of our complement-
resistant DAF-shielded BES-GL3 revealed for the first time that intravenously administered 
BV effectively transduces hepatocytes in vivo (Figure 2B). 
 
 
BV-mediated innate immune responses reject re-administration of BV 
 To examine antigen expression in vivo, I monitored luciferase expression in the mice 
by bioluminescence imaging on days 0, 1, 5, and 14 post-intramuscular injections of BV into 
the left anterior muscle of BALB/c mice (Figure 3A-D). We have previously shown that 
luciferase expression levels in intramuscular route were gradually reduced over time but 




Figure 2: Transgene expression and innate immune responses after BV 
administration via intravenous or intramuscular routes. (A, B) Luciferase 
expression at different timepoints after intramuscular (108 pfu) (A) or intravenous (107 
pfu) (B) administration of luciferase-expressing BES-GL3 (described as BV), detected 
by using the IVIS® Lumina LT in vivo imaging system. The heatmap visible in each 
mouse image represents the total flux of photons (p/sec/cm2) in that area. Rainbow 
scales are expressed in radiance (p/s/cm2/sr).    
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responses at the injection site or systemic immunity for more than 10 days, which is 
consistent with findings from previous studies (29). Moreover, intravenous administration of 
BES-GL3 initially increased the luciferase expression levels robustly, but the levels gradually 
decreased to 0% on the day 3 (Figure 3E-G), which is also stable with previous studies (33). 
Interestingly, when BV-Luc was intramuscularly re-administrated into the left tibialis anterior 
muscle at day 14, the luciferase expression was not detectable (Figure 3H). The result 
indicates that BV intravenous administration strongly induces innate immune responses 







Figure 3: Effects of BV administration. Luciferase expression at different time points 
after intramuscular (108 pfu) (A-D) or intravenous (107 pfu) (E-G) administration of 
BES-GL3 (BV) detected by using the IVIS® Lumina LT in vivo imaging system. After 
14 days intravenous BV administration mice were re-administered with BES-Luc (108 
pfu) by intramuscular route. The expression of luciferase was monitored on day 15 
(14+1) post-BV administration (H). (A-H) The heat map images visible in the mice 
represent the total flux of photons (p/s/cm2) in that area. 
	 14 
Recombinant BV induces inflammatory cytokines in both WT and TLR9-/- mice 
 Baculovirus virions displaying PbCSP administration was reported to elicit specific 
antibodies and gamma interferon (IFN-γ) and conferred protection against P. berghei 
challenge infection (40). Since IFN-γ is a critical component of antimalarial liver stage 
protective response (41), I examined the serum kinetics of proinflammatory cytokines 
following BES-GL3 intravenous administration. To explore the cellular immune responses, I 
first determined the Th1-type (IFN-γ and TNF-α) cytokine levels at various times (0, 3, 6, 9, 
12, 24, and 48 h) after BES-GL3 intravenous administration. IFN-γ and TNF-α levels rapidly 
reached their peaks at 6 h and decreased to baseline by 24 h  (Figure 4). 
 
 
 I also compared different cytokines (IFN-γ and TNF-α) production at 6 h after post-
BES-GL3 administration by intravenous and intramuscular routes (Figure 5A, B). 
Intravenous routes robustly produced both Th1-type cytokines levels compare with 
intramuscular route. In particular, IFN-γ and TNF-α level detected from sera of mice 
immunized with BES-GL3 by intravenous route was highly significant compared with 
control (p < 0.0001). On the other hand, intravenously administered mice with Ad-Luc and 




Figure 4: Kinetics of proinflammatory cytokines (IFN-γ and TNF-α). Kinetics of 
proinflammatory cytokines, IFN-γ (A) and TNF-α (B) in the sera at different timepoints 
post-BV intravenous administration (107 pfu) (n = 6). Line graph shows the increment of 




 CpG ODNs are known to induce IFN-γ secretion in previous studies (42). Gramzinski 
et al., reported that, IFN-γ might be involved in the CpG-induced protection against 
sporozoite challenge (43). As a positive control, less amount of IFN-γ was detected from 6 h 
intramuscular CpG ODN 1826 (50 µg) sera compare with BV (Figure 6A). The possible 
reason might be the B-type CpG ODNs which has a complete phosphorothioate backbone 
and induce the production of modest levels of IFN-α, with much weaker NK cell activation 
thus lower IFN-γ secretion (44).  
 BV is known to activate bone marrow-derived dendritic cells to induce the expression 
of activated cell-surface markers and to produce various kinds of cytokines (IL-6, IL-12p70, 
and TNF-α) (45). Since IL-12 has been implicated with a role in CpG ODN-induced 
immunity in other systems (46), so I compared the serum IL-12 levels 6 h post-BV 
intramuscular administration in WT mice (Figure 6B). Consistent with previous findings 
(43), CpG intramuscular administration induced a robust IL-12 response than BV 
administered sera. Results suggested that a strong inflammatory response with a complex 
pattern of inflammatory cytokines might contribute to the intrinsic immunogenic properties 




Figure 5: Comparison between different routes of BV-administration in terms of 
cytokine production. Levels of IFN-γ (A) and TNF-α (B) in the sera from WT mice 6 h 
after intramuscular and intravenous administration of BES-GL3 (described as BV) (108 
pfu), Ad-Luc (1010 pfu), or PBS (n = 6). Bars show the means ± SD. The difference from 
the PBS group was assessed by a one-way ANOVA with Dunn’s correction. ****p < 
0.0001. i.m., intramuscular; i.v., intravenous. 
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 To further investigate, I proceeded in TLR9-/- mice model for detection of different 
cytokines (IFN-γ and IL-12) production at 6 h after intramuscular administration of BES-GL3 
(Figure 7A, B). Significant amount IFN-γ was detected in both the TLR9-/- and WT mice. In 
particular, IFN-γ level detected from sera of TLR9-/- mice immunized with BES-GL3-Spider 
by intramuscular route was highly significant compared with TLR9-/- control group mice (p < 
0.0001). In contrast, less amount of IL-12 was detected in both TLR9-/- and WT group which 










Figure 6: Comparison between 6 h post-CpG ODN and BV-administration in terms 
of cytokine production in WT mice. Levels of IFN-γ (A) and IL-12 (B) in the sera 
from WT mice 6 h after intramuscular and intravenous administration of BES-GL3 
(described as BV) (108 pfu), CpG ODN  (50 µg), or PBS (n = 6-15). Bars show the 
means ± SD. The difference from the PBS group was assessed by a one-way ANOVA 




Intravenous BV-administration cause liver injury 
 Since previous study suggest that CD8+ T cell-mediated immune pathology occurs in 
the brain but not the liver, while parasite-dependent pathology occurs in both organs during 
P. berghei ANKA infection (47). Although BES-GL3 can completely eliminate the liver-
stage parasites, I was interested in liver damages caused by the BES-GL3 administration 
through different routes. To evaluate the liver damage, I first examined the serum kinetics of 
ALT and AST following BES-GL3 intravenous administration. The ALT and AST levels 










Figure 7: Recombinant baculovirus induces inflammatory cytokines in TLR9-/- 
mice. Levels of IFN-γ (A) and IL-12 (B) in the sera from TLR9-/- mice 6 h after 
intramuscular administration of BES-GL3 (described as BV) (108 pfu) or PBS (n = 6-
15). Bars show the means ± SD. The difference from the PBS group was assessed by a 




 I also measured liver damage markers levels after 6 h of BES-GL3 administration 
through different routes. Compared with intravenous administration, intramuscular 
administration did not affect the ALT levels; although the AST level trended higher 
following intramuscular administration, this difference did not reach statistical significance 
(Figure 9A-C). ALT is a sensitive indicator of liver damage (48), so these results suggest 
that, for BV, intramuscular administration may be less destructive than intravenous 
administration. Alternatively, if desired, intravenous administration can induce stronger 












Figure 8: Kinetics of liver damage markers (ALT and AST). Kinetics of liver 
damage markers, ALT (A) and AST (B), in the sera at different timepoints post-BV 
intravenous administration (107 pfu) (n = 6). Line graph shows the increment of the 
enzymes level with time. 
	 19 
 
BV administration elicits sterile protection against sporozoite  
Table 1 summarizes the protective efficacy results for BV administration against malaria 
sporozoite challenge. First, to examine the effects of BV intravenous administration, mice 
were intravenously administered 107 pfu of BES-GL3. At 6 h post-BV injection, which 
coincides with peak IFN-γ production, the mice were intravenously challenged by 1,000 Pb-
conGFP sporozoites, which are transgenic P. berghei constitutively expressing GFP. All BV-
injected mice were protected, whereas all PBS- and AdHu5-injected mice treated similarly 
became infected. Next, I investigated the effects of BES-GL3 intramuscular administration 
(108 pfu) followed by sporozoite challenge at various intervals post-BV injection. After 
intramuscular administration of BES-GL3, all mice were protected for at least 7 days. 
However, there was a complete loss of protection by 14 days post-BES-GL3 intramuscular 
	 	
	
Figure 9: Comparison between different routes of BV-administration in terms of 
liver enzymes. Comparison of ALT (A), AST (B), and both (C) values in the sera at 6 h 
after intramuscular (108 pfu) or intravenous (107 pfu) administration of BV (n = 6). Bars 
or points show the mean ± SD. The difference from the PBS group was assessed by a 
Kruskal-Wallis test with Dunn’s correction. ***p < 0.001. i.m., intramuscular; i.v., 
intravenous. 
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administration and no delay of parasitaemia was observed in these mice. Additionally, no 
protection was observed in mice treated intranasally with BES-GL3.  
BES-GL3 intravenous administration failed to provide protection against challenge with 
1,000 parasitized red blood cells (pRBCs) at 6 h post-BV injection, indicating that BV has no 
residual effect on blood-stage parasites. CpG intramuscular administration at 6 or 24 h prior 
to challenge conferred protection against sporozoite challenge in 90% or 80% of mice, 
respectively. This is consistent with previous work showing short-term (2-days) protection 
induced by CpG intramuscular administration (50 µg) against challenge with 100 P. yoelii 
sporozoites (43), although only partial protection (50%) was observed when the challenge 
occurred at 7 days post-CpG intramuscular injection. Thus, the protective efficacy induced by 
BES-GL3 intramuscular administration is more effective and longer-lasting (7-days) 
compared with that induced by CpG. All PBS-treated control mice developed blood-stage 
infection within 6 days following an intravenous injection of 1,000 Pb-conGFP sporozoites. 
 
Table 1. Protective efficacy of BV injection against P. berghei sporozoite challengea, b 
Treatmenta Dose (Routec) 





PBS (i.v.) 6 h 0 (0/8)e 
BV 1 x 107 pfu (i.v.) 6 h 100 (8/8) 
AdHu5-lucf 5 x 107 pfu (i.v.) 6 h 0 (0/3) 
PBS (i.m.) 12 h – 14 days 0 (0/20)e 
BV 1 x 108 pfu (i.m.) 12 h 100 (5/5) 
BV 1 x 108 pfu (i.m.) 24 h 100 (5/5) 
BV 1 x 108 pfu (i.m.) 3 d 100 (5/5) 
BV 1 x 108 pfu (i.m.) 5 d 100 (5/5) 
BV 1 x 108 pfu (i.m.) 7 d 100 (5/5) 
BV 1 x 108 pfu (i.m.) 14 d 0 (0/5) 
BV 1 x 108 pfu (i.n.) 6 h 0 (0/3) 
BV 1 x 107 pfu (i.v.) 6 h/1,000 pRBCg 0 (0/5) 
CpGh 50 µg (i.m.) 6 h 90 (9/10)e 
CpGh 50 µg (i.m.) 24 h 80 (4/5) 
 
aBALB/c mice were injected with BES-GL3 (described as BV) by the indicated route. After 
the indicated interval, mice were intravenously challenged with 1,000 Pb-conGFP 
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sporozoites. Parasitaemia was monitored on days 5-8, 11, and 14 after sporozoite challenge. 
Once parasites appeared in the blood, all mice died. 
bScheme of the experimental design is shown in Figure 19A. 
ci.v., intravenous; i.n., intranasal; i.m., intramuscular. 
dProtection is defined as the complete absence of blood-stage parasitaemia on day 14 post-
challenge.  
eCumulative data from two or four experiments. 
fBALB/c mice were intravenously injected with AdHu5-luc.  
gBALB/c mice were intravenously challenged with 1,000 Pb-conGFP-pRBC.  
hBALB/c mice were intramuscularly administrated with 50 µg of CpG ODN 1826 (described 
as CpG). 
 
BV administration completely eliminates of liver-stage parasites  
Pathways stimulated by type I and II IFNs can lead to the killing of hepatocytes infected 
with liver-stage parasites (8-13). Because BV is a potent inducer of type I and II IFNs (45, 
49), and I observed BV-mediated protection in Table 1, so in my next experiment I 
investigated whether BV-induced IFNs could kill liver-stage parasites in vivo. To examine 
the elimination effects on the trophozoite and exoerythrocytic (mature) schizont stages, I 
administered BES-GL3 intravenously or intramuscularly at two different intervals following 
sporozoite challenge, 24 and 42 h, respectively. Table 2 summarizes these results on the 
elimination efficacy of BES-GL3 administration against liver-stage parasites. Blood-stage 
parasites were completely prevented in all mice that had been intravenously injected with 
BES-GL3 at 24 h post-infection; in contrast, the protective effectiveness of BES-GL3 
intravenous administration was diminished when mice received it at 42 h post-infection 
instead. The same results were obtained when mice were intramuscularly injected with BES-
GL3. 
As PQ is the only licensed drug for the radical cure of P. vivax hypnozoites, I also 
compared the elimination effects of BV with those of PQ. Two different doses of PQ, high 
dose (2 mg/mouse) and low dose (0.1 mg/mouse), were intraperitoneally administered. A 
single administration of high dose of PQ completely eliminated the liver-stage parasites 
(Table 2), whereas a single low dose of PQ was unable to reduce liver parasite burden but 
caused a significant delay of parasitaemia (Figure 11). The WHO-recommended treatment 
schedule for PQ is 15 mg/day for 14 days, but because high doses of PQ often cause side 
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effects like nausea, vomiting, and stomach cramps, these side effects can limit patient 
compliance, potentially resulting in PQ resistance (50, 51). Thus, BV intramuscular 
administration may have important advantages of over PQ. 
 
Table 2. Elimination of liver-stage parasites by BV administrationa, b 
Treatmenta Dose (Routec) 





PBS (i.v.) 24 h 0 (0/12)e  
BV 1 x 107 pfu (i.v.) 24 h 100 (13/13)e 
BV 1 x 107 pfu (i.v.) 42 h 0 (0/3)  
PBS (i.m.) 24 h 0 (0/9)e 
BV 1 x 108 pfu (i.m.) 24 h 100 (7/7)  
BV 1 x 106 pfu (i.m.) 24 h 0 (0/5)f 
BV 1 x 104 pfu (i.m.) 24 h 0 (0/5)f  
BV 1 x 108 pfu (i.m.) 42 h 0 (0/3)f 
PQ (High)d 2 mg (i.p.) 24 h 100 (5/5) 
PQ (Low)d 0.1 mg (i.p.) 24 h 0 (0/5)f 
 
aBALB/c mice were intravenously injected with 1,000 Pb-conGFP sporozoites. After the 
indicated interval, mice were administrated either with BES-GL3 (described as BV) or PQ. 
Parasitaemia was monitored on days 5-8, 11, and 14 after sporozoite injection. Once parasites 
appeared in the blood, all mice died. 
bScheme of the experimental design is shown in Figure 19B.  
ci.v., intravenous; i.m., intramuscular; i.p., intraperitoneal. 
dThe two different doses of PQ as High (2 mg/100 µl) and Low (0.1 mg/100 µl) were 
administrated to eliminate liver-stage parasites.  
eCumulative data from three experiments. 
fSignificant delay of parasitaemia was observed in infected mice, compared with the PBS 







Detection of liver stage parasites elimination by in vivo imaging system  
 Our group generated a transgenic rodent malaria parasite (P. berghei) that consist of 
the luciferase gene under a promoter region of elongation factor-1α (33). The transgenic 
parasites designated Pb-Luc expressed luciferase in all stages of their life cycle. To visualize 
the parasite elimination by BV, mice were infected with Pb-Luc, which are transgenic P. 
berghei constitutively expressing luciferase, and then examined via IVIS; this is a highly 
sensitive method for detecting liver- and blood-stage parasites. Parasites were observed in the 
liver at both 24 h and 42 h post-infection (Figure 10A and B, respectively; left panels). BES-
GL3 intramuscular administration into the left thigh muscle at 24 h post-infection completely 
eliminated the liver-stage parasites completely at 72 h post-infection, whereas the PBS 
control treatment failed to prevent the development of blood-stage parasites (Figure 10A; 
right panel). Although BES-GL3 intramuscular administration into the right thigh muscle at 
42 h post-infection also failed to prevent the development of blood-stage parasites (Figure 
10B; right panel), it caused a significant delay of parasitaemia (Figure 11). The 
exoerythrocytic merozoites of P. berghei are released from infected hepatocytes into the 
blood stream at 44–48 h after the liver stage (52) Therefore, this result indicates that even for 
exoerythrocytic schizonts (42 h post-infection), the elimination effect of BV intramuscular 





BV possesses great prophylactic efficiency than CpG and primaquine 
 Next, I investigated whether BV possessed high prophylactic and therapeutic 
effectiveness than CpG and primaquine, respectively. Intramuscular administration of BES-
GL3 into the left thigh muscle at 24 h post-infection completely eliminated the liver-stage 
parasites at 72 h post-infection as mentioned before. While 42 h post-infection failed to 
prevent the development of blood-stage parasites but still caused a significant delay of 
parasitaemia (Figure 11). Results suggested that 42 h post-infection is too late to eliminate 




Figure 10: Effect of BV intramuscular administration on liver-stage parasites (A, 
B). Mice were challenged by infection with Pb-Luc sporozoites at 0 h, followed by 
intramuscular administration of BES-GL3 (108 pfu; described as BV) at the indicated 
timepoints. Luminescence in the liver indicates parasite growth, whereas that in the 
thigh shows the transgene expression by intramuscular BV injection. The heatmap 
visible in each mouse image represents the total flux of photons (p/s/cm2) in that area. 
Rainbow scales are expressed in radiance (p/s/cm2/sr). 
	 25 
blood-stage parasites. A single administration of high dose PQ completely eliminated the 
liver-stage parasites whereas a single low dose of PQ was suboptimal, producing only a 
reduction in parasite burden in the liver and caused a significant delay of parasitaemia 
(Figure 11). It was conventional that, pretreatment of mice with CpG ODN 1826 provided 
complete protection from infection when the CpG ODN 1826 was administered 1 or 2 days 
prior to P. yoelii sporozoites challenge (43). Consistent with the previous findings, CpG has a 
little effect on mature schizonts (24 h post-infection) as it caused a significant delay of 
parasitaemia (Figure 11). Results implicated that BV has an important potential for anti-liver 
stage drug. 
 
Liver stage parasites elimination efficacy is dependent on dose of BV 
Lower doses (104 and 106 pfu) of BES-GL3 administered at 24 h post-infection failed to 
prevent blood-stage parasites. However, a significant delay of parasitaemia was observed for 




Figure 11: Comparison among BV, CpG, and primaquine in the elimination of 
liver stage parasites. Delay of parasitaemia in infected mice. Parasitaemia of the groups 
of infected mice shown in Table 2 (108 pfu of BV injected intramuscularly at 42 h post-
infection, and PQ low dose administered at 24 h post-infection), and Table 3 (CpG 
administered 24 h post-infection). Bars or points indicate the mean ± SD. The difference 
from the PBS group was assessed by a two-way ANOVA. *p < 0.05, **p < 0.01, ****p 
< 0.0001. 
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dependent on the amount of BV that is intramuscularly administered. From the dose 
dependent study, I can conclude that 108 pfu BES-GL3-Spider dose is the best for the 
complete elimination of malaria parasites. 
 
 
BV-mediated liver-stage parasite killing occurs through TLR9-independent pathways 
CpG intramuscular administration completely eliminated early liver-stage parasites 
completely at 6 h post-infection (Table 3); however, although this treatment caused a 
significant delay of parasitaemia, it had little effect on mature schizonts (24 h post-infection) 
as mentioned in Figure 11. BV possesses unique characteristics that activate DC-mediated 
innate immunity through MyD88/TLR9-dependent and -independent pathways (14). 
Therefore, next I investigated whether TLR9 plays an important role in BV-mediated parasite 
killing in the liver. A single dose of intramuscularly administered BES-GL3 completely 
prevented blood-stage parasites in all TLR9-/- mice that had been previously infected with 





Figure 12: Dose dependency of BV on liver stage parasite elimination. Delay of 
parasitaemia in infected mice. Parasitaemia of groups of infected mice shown in Table 2 
(106 or 104 pfu of BV injected intramuscularly 24 h post-infection). Bars or points 
indicate the mean ± SD. The difference from the PBS group was assessed by a two-way 
ANOVA. **p < 0.01. 
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TLR9-/- mice following intramuscular administration of CpG (50 µg) (Table 3). These results 
clearly demonstrate that BV-mediated parasite killing occurs via TLR9-independent 
pathways. 
Table 3. Elimination of liver-stage parasites by BV injection in TLR9-/- micea 
Treatmenta Mouse strain Dose 





PBS TLR9-/- - 24 h 0 (0/7) 
BV TLR9-/- 1 x 108 pfu 24 h 100 (7/7) 
BV WT 1 x 108 pfu 24 h 100 (5/5) 
CpG WT 50 µg 6 h 100 (5/5) 
CpG WT 50 µg 24 h 0 (0/4)b 
CpG TLR9-/- 50 µg 24 h 0 (0/5) 
 
aTLR9-/- (BALB/c background) or WT mice were intravenously injected with 1,000 Pb-
conGFP sporozoites. After 24 h, mice were intramuscularly administrated either with BES-
GL3 (described as BV) or CpG ODN 1826 (described as CpG). Parasitaemia was monitored 
on days 5-8, 11, and 14 after sporozoite injection. Once parasites appeared in the blood, all 
mice died. 
bSignificant delay of parasitaemia was observed in infected mice, compared with the PBS 
group as shown in Figure 11. 
 
Intramuscular BV administration rapidly induces type I and II IFNs in sera 
BV intravenous administration was reported to produce type I IFNs through TLR-
independent and IRF3-dependent pathways in mice (14). To further investigate IFN 
production following BV intramuscular administration, the IFN serum levels were measured 
in WT and TLR9-/- mice at 6 h after BES-GL3 intramuscular administration. As with 
intravenous administration, intramuscular administration of BES-GL3 produced IFN-α in not 
only WT mice (6,311 ± 2,363 pg/ml) but also TLR9-/- mice (1,590 ± 737 pg/ml), whilst mice 
intramuscularly injected with PBS or CpG did not produce detectable IFN-α (< 20.0 pg/ml) 
(Figure 13A). IFN-γ, a type II IFN was also produced in both WT mice (1,367 ± 1,303 pg/ml) 
and TLR9-/- mice (488 ± 132 pg/ml) following intramuscular administration of BES-GL3 
(Figure 13B). Compared with BV, CpG intramuscular administration in WT mice induced 
much less IFN-γ but much more IL-12 (Figure 13C). Notably, CpG intravenous 
administration induced a high level of IFN-γ with considerable systemic side effects (53, 54). 
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These results indicate that BES-GL3 intramuscular administration induces production of both 
type I and II IFN via TLR9-independent pathways. 
 
 
Liver-stage parasites are killed by IFN-mediated immunity 
To determine whether the serum cytokines act as effectors against liver-stage parasites, a 
serum transfer assay was performed. Pooled sera were collected from donor mice at 6 h after 
they had been intramuscularly injected with BES-GL3 or PBS. An aliquot of the pooled sera 
(100 µl/animal) was transferred to each recipient mouse at 24 h after their intravenous 
injection with 1,000 sporozoites. One of the five recipient mice effectively eliminated the 




Figure 13: BV intramuscular administration BV administration rapidly induces 
type I and II IFNs in sera. (A-C) Levels of IFN-α (A), IFN-γ (B), and IL-12 (C) in 
sera from WT or TLR9-/- mice at 6 h after intramuscular administration of BES-GL3 
(described as BV) (108 pfu), CpG, or PBS (n = 9-10). Bars show means ± SD. The 
difference from the PBS group was assessed by a Kruskal-Wallis test with Dunn’s 
correction. **p < 0.01, ****p < 0.0001. 
	 29 
the time to 1% parasitaemia (mean delay of 3.54 days; p = 0.0008, compared with the PBS 
sera group) (Figure 14A).  
Next I examined whether neutralization of IFN-α or IFN-γ in the sera altered the effect of 
the sera on liver-stage parasites. Either anti-IFN-α or anti-IFN-γ antibody was incubated with 
100 µl of the sera, which contained 8,619 pg/ml of IFN-α and 4,705 pg/ml of IFN-γ. 
Complete neutralization of IFN-α was confirmed by ELISA (Figure 14B). The IFN-α- or 
IFN-γ-neutralized sera (100 µl) were intravenously administered to recipient mice that had 
been intravenously 24 h previously injected with 1,000 sporozoites. The anti-IFN-α antibody 
treatment completely abrogated the serum-induced delay of parasitaemia, whereas the anti-
IFN-γ antibody treatment only partially impaired the serum-induced elimination effect 
(Figure 14A). These data suggest that the IFN-γ-mediated killing may be mediated via an 
effector mechanism distinct from that activated by IFN-α. It is possible that the effector 
mechanism induced by IFN-α and IFN-γ might still have been synergistically operative but 




Figure 14: IFN-α induced by BV intramuscular administration contributes to 
elimination of liver-stage parasites. Results of a serum transfer assay to determine the 
role of IFN-α and IFN-γ in the elimination of liver-stage parasites (A). Sera collected 
from mice at 6 h after BV administration was neutralized by either anti-IFN-α or anti-
IFN-γ antibody. Passive transfer of antibody-treated sera, non-treated sera, or PBS was 
conducted at 24 h after sporozoite infection (n = 5). The difference from the PBS group 
was assessed by a Kruskal-Wallis test with Dunn’s correction. *p < 0.05, ***p < 0.001. 
Neutralization of IFN-α in sera from BV-administered mice (B). Aliquots of pooled sera 
from five BV-administered mice were neutralized by anti-IFN-α or anti-IFN-γ antibody. 
Complete neutralization of IFN-α was assessed by ELISA. Ab, antibody.  
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Role of exogenous IFNs in the elimination of liver-stage parasites 
To assess the effects of exogenous IFN-α and IFN-γ on the elimination of liver-stage 
parasites, recombinant IFN-α (8,619 pg/mouse) or recombinant IFN-γ (4,705 pg/mouse) was 
intravenously administered to mice that had been intravenously injected 24 h before with 
1,000 sporozoites. IFN-α administration eliminated the liver-stage parasites completely, 
whereas IFN-γ administration only partially eliminated them but caused a significant delay in 
the time to 1% parasitaemia (mean delay of 3.82 days; p = 0.0082, compared with the PBS 
group) (Figure 15). The IFN-α-mediated parasite elimination may be occur via an effector 
mechanism distinct from that activated by IFN-γ. It is also possible that the effector 
mechanisms induced by IFN-α and IFN-γ may still be synergistically operative but that an 
alternate protective mechanism may be activated by BV. Miller et al. similarly showed that 
IFN-γ produced by NKT cells following type I IFN signalling from infected hepatocytes play 
an important role in the elimination of liver-stage parasites (41). Result suggests that, the 
IFN-α-mediated parasite elimination may be mediated via an effector mechanism distinct 
from that activated by IFN-γ. Table 4 summarizes the results on the elimination efficacy 





Figure 15: Effect of exogenous IFN-α or IFN-γ on the elimination of liver-stage 
parasites. Recombinant mouse IFN-α or IFN-γ was intravenously administered at 24 h 
after sporozoite infection (n = 5). The difference from the PBS group was assessed by a 
Kruskal-Wallis test with Dunn’s correction. **p < 0.01. 
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Table 4. Elimination of liver-stage parasites by serum transfer and IFNsa,b 
Treatmenta Dose %Elimination (uninfected/total) 
Days to 1% parasitaemia 
(p value compared with PBS control group) 
Data from Fig. 14Ab    
PBS sera 100 µl  0 (0/5) 6.03 ± 0.08 
BV sera 100 µl  20 (1/5) 9.57 ± 0.38 (p = 0.0008)c 
BV sera treated with 
anti-IFN-α antibody 100 µl  0 (0/5) 6.18 ± 0.16 (p > 0.999) 
BV sera treated with 
anti-IFN-γ antibody 100 µl 0 (0/5) 7.59 ± 0.20 (p = 0.0288)
c 
    
Data from Fig. 15b    
PBS 100 µl  0 (0/5) 6.46 ± 0.13 
BV sera 100 µl  20 (1/5) 10.02 ± 0.14 (p = 0.0075)c 
Recombinant IFN-α 8,619 pg  100 (5/5) - 
Recombinant IFN-γ 4,705 pg 20 (1/5) 10.28 ± 0.41 (p = 0.0082)c 
 
aBALB/c mice were intravenously injected with 1,000 Pb-conGFP sporozoites. After 24 h, 
mice were treated as indicated. Parasitaemia was monitored on days 5-11, and 14 after 
sporozoite injection. Once parasites appeared in the blood, all mice died. 
bSchemes of the experimental designs are shown in Figure 19, C and D. 
cSignificant delay of parasitaemia was observed in infected mice, compared with the PBS 
control group by Kruskal-Wallis test. 
 
IFN-stimulated genes (ISGs) are upregulated in the liver after BV intramuscular 
administration 
Signal transduction of type I IFNs results in the induction of numerous ISGs (55). Some 
ISGs participate in direct antimicrobial activities, such as apoptosis induction and post-
transcriptional event regulation of microbial killing, mainly acting as antiviral responses. 
Gene-targeting studies have distinguished four effector pathways of the IFN-mediated 
antiviral response: the Mx GTPase pathway, 2′-5′ oligoadenylate-synthetase (OAS)-directed 
ribonuclease L pathway, protein kinase R (PKR) pathway, and ISG15 ubiquitin-like pathway 
(56). Additionally, several ISGs, such as IFN-induced proteins with tetratricopeptide repeats 
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(IFITs), as well as the transcription factors IRF3 and IRF7 are responsible for sensing the 
liver-infection by Plasmodium sporozoites (13). To confirm the involvement of ISGs, the 
gene expression levels in the livers of mice that had been intramuscularly injected with BES-
GL3 were measured by quantitative RT-PCR (qRT-PCR). BES-GL3 significantly induced 
the gene expression of several antiviral proteins (Isg15, Mx1, Oas1a/b, Oasl1, and Pkr) in 
WT mice (Figure 16). All these genes, except Oas1a/b, possibly due to the gene locus, were 
also upregulated by BV in TLR9-/- mice. 
 
 
Recent study demonstrated that similar subsets of ISGs such as Ifit1, Ifit3, and Ifit44 were 
upregulated by Plasmodium liver-stage infection as a type I IFN response (13). In my study, 
the expression levels of such genes were significantly induced by the immunization of BES-
GL3 with much higher extent than that by Plasmodium infection (Figure 17). Consistent with 
the profile of other ISGs, Ifit1, Ifit3, and Ifit44 were upregulated in TLR9-/- mice immunized 
with BES-GL3 (Figure 17). 
 
 
Figure 16: ISG induction in the liver after BV intramuscular administration. Gene 
expression of antiviral proteins in the livers of WT and TLR9-/- mice at 6 h after 
intramuscular administration of BES-GL3 (described as BV) (108 pfu) was measured by 
real-time RT-PCR (n = 5-7). Bars show means ± SEM. The difference from the PBS 
group was assessed by a Mann-Whitney’s U test. *p < 0.05, **p < 0.01. 
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Expressions of type I IFNs after the microbial recognition were regulated by two 
transcription factors, interferon regulatory factor (IRF) IRF3 and IRF7. Interestingly, the 
expression levels of IRF3 and IRF7 were significantly enhanced in the liver, far from the 
injection site, after the immunization of BES-GL3 (Figure 18); the high expression of the 
transcription factors might further enhance the autocrine/paracrine-gene expression during a 
type I IFN-signaling pathway. Regardless of the TLR9-signaling pathway, the expressions of 
IRF3/7 were induced by BES-immunization (Figure 18). These results indicate that systemic 
type I IFN secretion following BV intramuscular administration in the thigh muscle strongly 









Figure 17: BV intramuscular administration induces IFITs in the liver. Gene 
expression of IFITs in the livers of WT and TLR9-/- mice at 6 h after intramuscular 
administration of BES-GL3 (described as BV) (108 pfu) was measured by real-time RT-
PCR (n = 5-7). Bars show means ± SEM. The difference from the PBS group was 




An AdHu5-prime/BDES-boost heterologous immunization regimen confers sterile 
protection and complete elimination 
To evaluate our previously developed malaria vaccine in an AdHu5-prime/BDES-boost 
heterologous immunization regimen (19), mice were challenged twice, once before and once 
after the BDES-PfCSP-boost. All the fully immunized mice were protected against both the 
first and second challenges (Table 5, Group 2). In contrast, AdHu5-prime immunization 
alone did not confer protection (Group 1). Although BES-GL3 intravenous administration 
completely eliminated the liver-stage parasites (Group 4), there was no protection against 2nd 
challenge 21 days after 1st challenge. All control mice intramuscularly injected with PBS 
became infected (Groups 3 and 5). Thus, BDES-PfCSP boosting was able to exert not only a 
therapeutic effect on liver-stage parasites but also a prophylactic effect on sporozoites. These 
results indicate that AdHu5-prime/BDES-boost heterologous immunization regimen 
eliminates the liver-stage parasites by BV-mediated innate immune responses and protects 
against challenge by vaccine-specific adaptive immune responses. The animal experimental 





Figure 18: BV intramuscular administration induces IRFs in the liver. Gene 
expression of IRFs in the livers of WT and TLR9-/- mice at 6 h after intramuscular 
administration of BES-GL3 (described as BV) (108 pfu) was measured by real-time RT-
PCR (n = 5-7). Bars show means ± SEM. The difference from the PBS group was 
assessed by a Mann-Whitney’s U test. *p < 0.05. 
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aSchemes of the experimental designs are shown in Figure 19, E and F. 
bBALB/c mice were intramuscularly immunized with AdHu5-PfCSP (described as AdHu5). 
After 3 weeks, mice were intramuscularly injected with PBS 24 h following intravenously 
injected with 1,000 1,000 PfCSP-Tc/Pb sporozoites. Parasitaemia was monitored on days 5, 6, 
7, 8, 11, and 14 after sporozoite injection. Once parasites appeared in the blood, all mice died.  
cBALB/c mice were intramuscularly immunized with AdHu5. After 3 weeks, mice were 
intramuscularly injected with BDES-PfCSP (described as BDES) 24 h following 
intravenously injected with 1,000 PfCSP-Tc/Pb sporozoites. Protected mice were 2nd-
challenged 21 days after 1st challenge. 
dBALB/c mice were intramuscularly immunized with PBS. After 3 weeks, mice were 
intramuscularly injected with PBS 24 h following intravenously injected with 1,000 PfCSP-
Tc/Pb sporozoites. The group 3 was used as a control infection for 1st challenge of the groups 
1 and 2. 
eBALB/c mice were intravenously immunized with BES-GL3 (described as BV). After 6 h, 
mice were intravenously challenged with 1,000 PfCSP-Tc/Pb sporozoites. Protected mice 
were 2nd-challenged 21 days after 1st challenge.  
fBALB/c mice were intramuscularly immunized with PBS twice at day 0 and 21. After 3 
weeks, mice were intravenously challenged with 1,000 PfCSP-Tc/Pb sporozoites. The group 
5 was used as a control challenge for 2nd challenge of the group 4. 
Group Prime Boost 
Time interval 









1b AdHu5-sPfCSP2 PBS 
24 h before 
boost 




24 h before 
boost 100 (5/5) 




3d PBS PBS 24 h before boost 0 (0/10) - - 
4e - BV 6 h before challenge 100 (8/8) 




5f PBS PBS 21 d after boost 0 (0/5) - - 
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Experimental design 
 The clinically silent pre-erythrocytic stages of mammalian Plasmodium spp, 
composed of both the sporozoite and liver stages are ideal targets for vaccine interventions 
and prophylactic drug discovery. Because if infection is blocked at these stages, there will be 
no subsequence blood-stage parasites and therefore neither clinical symptom nor 
transmission. My present study aim to assessed the capability of the BV-induced innate 
immune responses to protect mice against malaria pre-erythrocytic stage. My main focus was 
to target the Plasmodium parasites that reach the liver and invade hepatocytes to ultimately 
prevent the release of merozoites that will infect red blood cells. The experimental design are 















Figure 19: Experimental design. Mice were intravenously, intramuscularly, or 
intranasally administered BES-GL3 (described as BV) or CpG followed by an 
intravenous challenge with 1,000 Pb-conGFP sporozoites or 1,000 iRBC at various time 
intervals (6 h–14 days). The results are shown in Table 1 (A). Mice were intravenously 
injected with 1,000 Pb-conGFP sporozoites. At 24 or 42 h after liver-stage development, 
the mice were injected with either BV, CpG, or PQ. The results are shown in Table 2 
and 3 (B). Pooled sera were obtained from donor mice that had been intramuscularly 
injected with BV 6 h before. Recipient mice were intravenously injected with 1,000 Pb-
conGFP sporozoites. After 24 h, the recipient mice were intravenously injected with 
either non- treated pooled sera or pooled sera that had been treated with anti-IFN-α, or 
anti-IFN-γ antibody. The results are shown in Figure 14A (C). Mice were intravenously 
injected with 1,000 Pb-conGFP sporozoites. At 24 h after liver-stage development, the 
mice were intravenously injected with either IFN-α or IFN-γ. The results are shown in 
Figure 15 (D). Mice were intramuscularly immunized with an AdHu5-prime and PBS-
boost regimen with a 3-weeks interval. The mice were intravenously challenged with 
1,000 PfCSP-Tc/Pb sporozoites at 24 h before PBS boosting. The results are shown in 
Table 5 (E). Mice were intramuscularly immunized with a heterologous AdHu5-prime 
and BDES-boost regimen with a 3-weeks interval. The mice were intravenously 
challenged with 1,000 PfCSP- Tc/Pb sporozoites at 24 h before BDES boosting (first 
challenge). Protected mice were re- challenged in the same manner at 21 days after the 





 Before the clinical phase of malaria infection in blood stage, Plasmodium sporozoite 
parasites, injected by a female Anopheles mosquito, travel to the liver and infect hepatocytes. 
The liver-stage parasites asymptomatically produce thousands of merozoites that will 
subsequently infect erythrocytes. Therefore, effective innate immune responses raised before 
or during the liver-stage infection could prevent the onset of disease. In this study, I focused 
on characteristics features of BV with activation of innate immunity. The aim of my study 
was to assess the capability of the BV-induced innate immune responses for protecting mice 
against malaria pre-erythrocytic stage along with its adjuvant properties. Here I demonstrate 
that BV intramuscular administration not only elicits short-term sterile protection against 
sporozoite infection but also eliminates liver-stage parasites completely.  
 
Probable mechanisms for complete elimination of liver-stage parasites by baculovirus  
 This study showed that IFN-α and IFN-γ were rapidly and robustly produced in serum 
at 6 h post-BV intramuscular administration in a TLR9-independent manner and upregulates 
ISGs expression in the liver. In addition, in vivo passive transfer of the serum effectively 
eliminated liver-stage parasites that were fully abolished by neutralization of IFN-α. This 
result was consistent with the finding that intravenous administration of IFN-α completely 
eliminated the liver-stage parasites. Thus, I observed that type I IFN signaling pathway play 
an important role in the killing mechanism of liver-stage parasites. Interestingly, the 
prophylactic effect against sporozoite infection persisted for at least 7 days, even though IFN-
γ and TNF-α serum levels returned to baseline by 24 h. I speculate that the prophylactic 
effect at day 7 post-BV administration may be due to the killing of parasites in the liver rather 
than to an invasion blockade mediated by serum components. In the case of ‘natural’ 
Plasmodium liver-stage infection, the infected hepatocytes induce IFN-α, resulting in a 
reduction of the liver-stage burden (13). However, the parasite-induced IFN-α responses fail 
to eliminate every parasite. This implies that the endogenous innate immune responses may 
be not strong enough for complete elimination and/or that the innate immune response peak 
occurs at the end of liver-stage development, just prior to or concurrent with exoerythrocytic 
merozoites release (57). Otherwise, the parasite has probably devised strategies to counteract 
it, eg., inhibition of apoptotic pathways of the host hepatocyte to ensure their own survival 
(57). Compared with the type I IFN induced by host sensing of parasites, the quantity of BV-
induced type I IFN and its speedy induction may make it more effective, resulting in its 
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potent therapeutic and prophylactic effects. My results are consistent with recent data from 
Liehl et al. reporting that the ISGs induced in infected hepatocytes by a high dose of 
sporozoites reduced the liver-stage burden (13). Collectively, these data suggest that the 
innate immune responses induced by intramuscular injection of BV comprise not only IFN 
production but also activation of an unknown pathway(s) in the liver and that BV injection 
induces these more rapidly and effectively than does sporozoite infection.  
 Gronowski et al. initially demonstrated that BV induced type I IFN from murine and 
human cell lines and conferred in vivo protection of mice from encephalomyocarditis virus 
infection (58). Recently, Ono et al. reported that after being transduced, the host cells senses 
BV genomic dsDNA via the cytosolic DNA sensor STING recognition, resulting in the 
production of type I IFN in response to BV transduction via TLR9-independent pathway 
(59). Abe et al. also demonstrate the BV-induced type I IFN is TLR9-dependent and -
independent pathways (14). Zheng et al. showed that TLR2 but not other TLRs is involved in 
recognition of invading sporozoites and initiate innate immune responses against intrahepatic 
parasites (60). The produced type-I IFNs alert the surrounding cells by triggering signaling 
cascades that lead to phosphorylation and nuclear translocation of STAT1 (60). Hervas-
Stubbs et al. also showed that BVs have strong adjuvant properties, promoting humoral and 
CTL responses against the coadministered antigen, DC maturation, and the production of 
inflammatory mediators through mechanisms primarily mediated by type-I IFN (61). 
 However, the precise mechanisms by which BV activates STING in vivo remain 
unclear. Type I IFNs can also be induced by host factors and cytokines such as TNF, which 
signal via IFN-regulatory factor 1 (IRF1) rather than via IRF3 and IRF7, and by macrophage 
colony stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL) (62). 
Contrarily, IFN-γ plays an important role in the elimination of liver-stage Plasmodium 
parasites, but the mechanism involved in this process is unclear. Additional in vivo study 
validated the importance of IFN-γ in protective immunity as it inhibits intracellular 
development of parasite within hepatocytes following challenge with P. berghei (10), P. 
yoelii (63), or P. vivax sporozoites (11) in mice and chimpanzee, respectively. Recently, 
Miller et al. demonstrated that IFN-γ secreted in primary P. yoelii sporozoite infection is the 
key innate mediator that controls liver-stage parasite growth in a secondary infection (41). 
More recently, Lelliott and Coban remarked that IFN-γ protects hepatocytes against P. vivax 
infection via LAP-like degradation of sporozoites (64). In contrast to that report, the present 
study shows that substantial amount of IFN-γ in sera induced by intramuscular BV 
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administration had little effect on the parasite elimination in vivo. My results on IFN-α and 
IFN-γ suggest that IFN-α stimulation quickly activates downstream of its signaling pathway, 
compared with IFN-γ stimulation, and in vivo IFN-γ stimulated parasite killing in the liver 
may require much higher concentration of IFN-γ (400 U IFN-γ/mL) against much earlier 
liver-stage parasites (4 h after infection). For vaccine development against the pre-
erythrocytic stage, it has been widely accepted that an ideal vaccine should induce IFN-γ-
mediated cellular immune responses. 
 The present study showed that IFN-α, TNF-α, and IFN-γ were rapidly and robustly 
produced in serum 6 h following BV administration. Consistent with my data, Nishibe et al. 
reported that intraperitoneal BV administration alleviates dimethylnitrosamine-induced liver 
cirrhosis symptoms through type I and II IFNs in a murine model (65). Remarkably, there are 
~300 interferon-stimulated genes which are linked to the type I IFN signaling pathway (55, 
66, 67). Isg15, Mx1, OAS1, OASL, and PKR genes, which are well-known as antiviral 
effectors (56), were up-regulated in the hepatocytes by BV intramuscular administration. It is 
also of interest to explore cross-regulations between type I and II IFNs for signaling into 
infected hepatocytes and Kupper cells. A better understanding of the molecular mechanisms 
by which BV administration confers both protection and elimination of pre-erythrocytic 
parasites will provide new strategies for malaria drug and vaccine development. 
 
Application in drug development 
 For liver-stage parasites proliferating vigorously at 24 h post-infection, the BV-
induced fast-acting innate immune responses completely killed them within the following 20 
h and prevent blood-stage parasite development in the absence of any clinical symptoms, 
which is more effective than PQ in a mouse model with early liver-stage P. berghei. A major 
challenge for strategies combating the human malaria parasite P. vivax is the presence of 
hypnozoites in the liver. PQ is currently the only available drug that kills the dormant 
hypnozoites of P. vivax, but its severe side effects in G6PD-deficient people prevent the 
widespread use of this drug (68). The P. berghei liver-stage model is thought to correlate 
with anti-hypnozoite activity in primates (69). The presence of hypnozoites and their drug-
insensitivity form a major hurdle for malaria elimination programmes, and it is generally 
agreed that the mission to eradicate malaria initiated by Bill and Melinda Gates (70) can only 
be successful if effective means exist to remove this hidden reservoir of hypnozoites from the 
population (71, 72). The present study shows that BV is more effective than PQ in a mouse 
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model with early liver-stage P. berghei, which is thought to correlate with anti-hypnozoite 
activity in primates (69). To date, the closely related malaria parasite P. cynomolgi, which 
infects non-human primates, has been the gold-standard in vivo model for studying 
hypnozoites (73). Although P. berghei does not have a dormant hypnozoite stage, it is 
possible that the therapeutic effect of BV against liver-stage infection may provide clues on 
how to eliminate hypnozoites. Further experiments in the P. cynomolgi model are needed to 
evaluate the potential of BV as a new non-haemolytic single-dose alternative to PQ. Thus, 
BV offers a promising new non-haemolytic single-dose alternative to PQ for first-in-human 
clinical trials. Further experiments to determine optimum BV administration routes and 
dosages are needed. 
 
Application in vaccine development 
 BV possesses attractive attributes as a new vaccine vector, including its low 
cytotoxicity, inability to replicate in mammalian cells, absence of pre-existing antibodies 
against it, display of the vaccine antigen on the viral envelope with near-naïve form (known 
as “baculophage”), transduction of mammalian cells (known as “BacMam”), and function as 
both a vaccine component and a DNA vaccine (known as “baculovirus dual-expression 
system-BDES”) (17). This study suggests a further unique advantage of BV as a vaccine 
additive with short-term protection against malaria via its intrinsic potent immunostimulatory 
property. Generally, adaptive immunity induced by vaccines takes several days to become 
effective and often requires two or three doses. Even effective licensed vaccines cannot 
protect individuals from the target pathogen immediately after vaccination. Therefore, in 
addition to long-term protective immunity, it is ideal that a next-generation vaccine could 
induce effective short-term non-specific immunity to minimize the risk of infection during 
the vaccination schedule. In a Phase II–III malaria vaccine trials, all volunteers are 
presumptively treated with three daily doses of anti-malaria drug for one week before the 
final vaccination and rechecked for asexual P. falciparum parasitaemia at one week after the 
final vaccination. Any subject who tests parasite-positive is treated with a second line drug or 
excluded from the trial (74). Thus, clinical trials aim to test vaccine efficacy after all vaccine 
schedules are completed to assess the maximum effect. For clinical application, however, 
vaccine recipients remain in danger of infection until the full vaccination schedule is 
completed, even though improved effective vaccine would be developed. If BV was co-
administered as an additive with a newly developed malaria vaccine like RTS,S, the joint 
vaccine would be expected to not only minimize the risk of infection for vaccine recipients 
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during the vaccination schedule but also generate robust and long-lasting adaptive immune 
responses via innate immune system stimulation by BV acting as an adjuvant. Our previous 
study showed that repeated administration of BV reduces its transduction efficacy by 
antibody-mediated neutralization (23). Further studies are needed to address whether the 
induction of innate immune responses by BV is linked to its transduction efficacy. This study 
also shows that our newly developed heterologous AdHu5-PfCSP-prime and BDES-PfCSP-
boost vaccine eliminated liver-stage parasites that had infected the mice 24 h before 
administration of the BDES-boost and also elicited sterile protection against sporozoite 
challenge 21 days post-boost. We propose that BV-based vaccines can not only minimize the 
risk of infection for vaccinators during the vaccination schedule but also generate robust and 
long-lasting adaptive immune responses via stimulation of the innate immune system. 
Alternatively, BV itself may also be used as an additive to eliminate liver-stage parasites and 
impart this short-term protection to RTS,S or other licensed vaccines. 
 
Application in IFN-α immunotherapy 
 IFN-α has been extensively explored for its efficacy in various disease conditions and 
is currently used as a standard treatment in several illnesses, especially chronic hepatitis C 
(HCV) for which IFN-α has been used as the only approved treatment since 1991. However, 
its use is accompanied by a wide variety of possible side effects (75), such as autoimmune 
thyroiditis. Moreover, the standard treatment of HCV with IFN-α and ribavirin can cost an 
average of US$22,000, and, depending on genotype, as few as 42% of treated individuals 
subsequently clear the infection (76). 
 I found that BV intramuscular administration, which induced 8,619 pg/ml of IFN-α in 
mouse sera while maintaining normal ALT levels, completely killed liver-stage parasites. The 
manufacturing cost of BV would be much lower than that of rIFN-α. Thus, BV intramuscular 
administration also has great potential for use as an alternative IFN-α-based immunotherapy; 
its high biological activity, cost-effectiveness, non-invasive nature, and minimal adverse 
effects make it superior to the current IFN-α therapy using recombinant IFN-α via 
intravenous administration. Although the present study consistently used a DAF-shielded 
BES-GL3 to monitor transgene expression in the liver and muscle, WT AcNPV should exert 
the same function as BES-GL3 in terms of IFN-α production and anti-parasite effects. Future 
work should investigate whether other Baculoviridae family members can induce more 
effective killing of liver-stage parasites.  
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 In conclusion, BV effectively induces fast-acting innate immune responses that 
provide powerful first lines of both defensive and offensive attacks against pre-erythrocytic 
parasites. My results illustrate the potential of BV as a new potent prophylactic and 
therapeutic immunostimulatory agent against pre-erythrocytic-stage parasites. Even though 
the First-in-Human trials of BV have not yet been conducted, our previous study showed that 
the BV-based vaccine vector is safe and well-tolerated with acceptable reactogenicity and 
systemic toxicity in a primate model (18). In addition, the BV system itself has proven to be 
clinically suitable and has been approved for the purposes of vaccination. BV-based vaccines 
include Cervarix (GlaxoSmithKline, Rixensart, Belgium), a human papillomavirus (strain 16 
and 18) viral-like particle vaccine against cervical cancer, and Provenge (Dendreon Inc., 
Seattle, USA), which is an immune-therapeutic vaccine against prostate cancer. Although 
further studies are needed to clarify the prophylactic and therapeutic effects of BV in a non-
human primate malaria model (e.g. doses and repeated treatment), our results highlight useful 
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